期刊
ANNALS OF PHARMACOTHERAPY
卷 42, 期 3, 页码 408-412出版社
HARVEY WHITNEY BOOKS CO
DOI: 10.1345/aph.1K345
关键词
irritable bowel syndrome; rifaximin; small intestinal bacterial overgrowth
OBJECTIVE: To evaluate the role of rifaximin in the treatment of symptoms associated with irritable bowel syndrome (IBS). DATA SOURCES: Clinical literature was accessed through MEDLINE (1990-September 2007) using the terms rifaximin, small intestinal bacterial overgrowth (SIBO), bacterial overgrowth, and irritable bowel syndrome. Additionally, references in publications identified in the search were reviewed for relevant information. STUDY SELECTION AND DATA EXTRACTION: All articles published in English identified from the data source were evaluated. Randomized clinical trials in adult populations were included. DATA SYNTHESIS: IBS is a common functional bowel disorder of unknown etiology. Some evidence suggests that symptoms are secondary to bacterial overgrowth in the small intestine. Rifaximin, a nonsystemic antibiotic that targets the gastrointestinal tract, has been evaluated in the treatment of SIBO. Six studies that evaluated rifaximin in either IBS, with or without documented SIBO, or SIBO alone, were reviewed. Significant symptom improvement was reported, and in some Gases, correlated with reductions in hydrogen breath tests, suggesting successful treatment of bacterial overgrowth. Data are limited by controversial diagnostic techniques for SIBO, small sample sizes, the unpredictable course of the disorder, and variability in clinical trial methodology that prevents direct comparison. CONCLUSIONS: Rifaximin offers a potential new therapeutic option for patients with refractory IBS. Larger, well-designed trials are necessary to elucidate the role of rifaximin in the treatment of this disorder.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据